Navigation Links
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients

* Treatment with ISIS 301012 produced at least 45% additional reduction in patients' LDL-cholesterol when added to maximally-tolerated lipid-lowering therapies

CARLSBAD, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced updated results from its ongoing Phase 2 clinical trial of ISIS 301012 in patients with homozygous familial hypercholesterolemia (HoFH), initial results of which were presented in March at the of Cardiology Annual Scientific Session (ACC) in New Orleans. The three HoFH patients dosed with 300 mg/week of ISIS 301012 for twelve weeks have now completed treatment. With ISIS 301012, the patients achieved 45%, 50% and 51% additional reductions in LDL-cholesterol beyond that achieved with maximally-tolerated lipid-lowering therapy, with similar reductions in apoB of 45%, 43% and 54%. ISIS 301012 continued to be well tolerated in the study.

"The magnitude of LDL-cholesterol response in these three HoFH patients has surpassed anything I have seen in the last 30 years, including with statins," stated Evan Stein, M.D., Ph.D., Director, Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, lead investigator in the study. "It offers for the first time the potential for good, life-long control of LDL without expensive and invasive therapies such as apheresis, liver transplantation and other heroic measures we have tried over the years."

ISIS 301012 has been granted orphan drug status for the treatment of homozygous FH, one of the most severe forms of hypercholesterolemia and one that is highly resistant to treatment. Patients with this genetic condition typically suffer heart attacks at an early age. Isis plans to begin registration-directed studies for FH in 2007.

ISIS 301012 in Homozygous Familial Hypercholesterolemia

The data presented are part of a single-arm, open-label, dose-escalation study. Because the study was designed princip
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:5/22/2015)... de mayo de 2015 Dipexium ... compañía farmacéutica de fase tardía centrada en ... cream 0.8%), y colaboradores de investigación clínica, ... destacando el diseño innovador de los ensayos ... que evalúan Locilex®, su nuevo péptido de ...
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... 22, 2015 The Assistance Fund announces the ... provides financial assistance for copay to individuals diagnosed with ... the addition of the Melanoma Copay Assistance Program to ... , executive director. "With each additional program we are ... world where no one is denied access to medications ...
Breaking Medicine Technology:Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2The Assistance Fund Adds Melanoma Assistance Program 2
... Life Length, the world,s leading telomere testing and services ... have joined its Scientific Advisory Board ("SAB"). ... delighted to welcome these world-renowned telomere and telomerase experts ... global leadership.  Dr Chang is especially well known for ...
... Colo., March 6, 2012   Heska Corporation (NASDAQ: ... veterinary diagnostic and other specialty veterinary products , today ... of best practices research, tools and metrics for patent ... again ranked Heska,s Science Strength in the top 50 ...
Cached Medicine Technology:Drs Sandy Chang and Kathleen Collins Join LIFE LENGTH®'s Scientific Advisory Board 2The Patent Board Ranks Heska's Science Strength in Biotechnology Industry Top 50 2The Patent Board Ranks Heska's Science Strength in Biotechnology Industry Top 50 3
(Date:5/23/2015)... (PRWEB) May 23, 2015 On May 16, ... MuckFest. The event was a 5k mud obstacle run that ... than 2 million people worldwide, and the reason we participated ... said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred percent ... Sclerosis Society.” , The event was not only attended by ...
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ProFlare ... simple as dragging and dropping footage into the FCPX timeline ... , Including over 80 stunning flares, ProFlare 5K Prism ... the ultimate bundle for adding prismatic refractions to any video. ... movie files designed for Final Cut Pro X, but are ...
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health Limited ... brand Nature’s Way, Marc St-Onge has affirmed his commitment ... is an integral part of the agreement with Nature’s ... further develop Ascenta Skin into a leading player in ... breakthrough, anti-aging skincare supplement featuring 6 active ingredients including ...
(Date:5/22/2015)... “It’s like learning an new ... Vice President of Clinical Operations/Education and Training at ... impacts how care is coded and reimbursed.” , ... care reimbursement, operations and compliance consulting, as well ... launches a new series of day-long seminars on ...
Breaking Medicine News(10 mins):Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:ACTCM Announces Upcoming June Events 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... of Medicine Department of Ophthalmology and Visual Sciences has ... awards that could total up to $1 million by ... the most grants awarded in a single year to ... In that time, the program received $2,712,500 from RPB, ...
... Study Shows Long-term Influence of Family ConflictBOSTON, March 9 ... lasting impact on an individual,s mental health and functioning ... the March edition of The Journal of the ... The longitudinal study, led by Simmons School of Social ...
... Teikoku Pharma USA Inc., the international specialty pharmaceutical ... worldwide (excluding Japan) licensing agreement with Eisai Co., ... formulation of donepezil, a leading compound for the ... transdermal formulation is a once-a-week patch that continuously ...
... electronically and efficiently manage and document their control ... Omnicell, Inc. (Nasdaq: OMCL ) a ... facilities, today introduced its Omnicell Tissue Center solution, ... with the latest release of Omnicell OptiFlex(TM) 10.0 ...
... Multiple Sclerosis Society is a driving force in creating a ... Society continues to seek ways to prevent, slow the progression ... is by supporting scientifically meritorious medical research, including research using ... state and local laws and with adherence to the strictest ...
... 9 Beckman Coulter, Inc. (NYSE: BEC ), a ... innovate complex biomedical testing, announced today that Charlie Slacik, Beckman Coulter,s ... following conferences:, , ... 2009 at 2:00 p.m. (ET). , , ...
Cached Medicine News:Health News:Case Western Reserve awarded nearly $1 million from Research to Prevent Blindness Foundation 2Health News:A Lesson for Parents: Arguing in Front of Your Teens Has Lasting Impact, Researchers Find 2Health News:Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil. 2Health News:Omnicell Unveils Tissue Center Solution - Industry's First Integrated Tissue Tracking and Compliance System 2Health News:Omnicell Unveils Tissue Center Solution - Industry's First Integrated Tissue Tracking and Compliance System 3Health News:National Multiple Sclerosis Society Commends President Obama's Initial Steps in Removing the Bans on Embryonic Stem Cell Research 2Health News:Beckman Coulter to Present at Upcoming Healthcare Conferences 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: